These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
751 related articles for article (PubMed ID: 35674109)
1. Cellular senescence and the tumour microenvironment. Takasugi M; Yoshida Y; Ohtani N Mol Oncol; 2022 Sep; 16(18):3333-3351. PubMed ID: 35674109 [TBL] [Abstract][Full Text] [Related]
2. The role of cellular senescence and SASP in tumour microenvironment. Takasugi M; Yoshida Y; Hara E; Ohtani N FEBS J; 2023 Mar; 290(5):1348-1361. PubMed ID: 35106956 [TBL] [Abstract][Full Text] [Related]
3. Effects of senescence on the tumour microenvironment and response to therapy. Reynolds LE; Maallin S; Haston S; Martinez-Barbera JP; Hodivala-Dilke KM; Pedrosa AR FEBS J; 2024 Jun; 291(11):2306-2319. PubMed ID: 37873605 [TBL] [Abstract][Full Text] [Related]
4. Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy. Özdemir A; Şimay Demir YD; Yeşilyurt ZE; Ark M Adv Protein Chem Struct Biol; 2023; 133():115-158. PubMed ID: 36707199 [TBL] [Abstract][Full Text] [Related]
5. Assessing Functional Roles of the Senescence-Associated Secretory Phenotype (SASP). Malaquin N; Tu V; Rodier F Methods Mol Biol; 2019; 1896():45-55. PubMed ID: 30474839 [TBL] [Abstract][Full Text] [Related]
6. The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis? Ohtani N Inflamm Regen; 2022 Apr; 42(1):11. PubMed ID: 35365245 [TBL] [Abstract][Full Text] [Related]
7. Reshaping of the tumor microenvironment by cellular senescence: An opportunity for senotherapies. D'Ambrosio M; Gil J Dev Cell; 2023 Jun; 58(12):1007-1021. PubMed ID: 37339603 [TBL] [Abstract][Full Text] [Related]
8. Senescence and Immunotherapy: Redundant Immunomodulatory Pathways Promote Resistance. Oesterreich S; Aird KM Cancer Immunol Res; 2023 Apr; 11(4):401-404. PubMed ID: 36826438 [TBL] [Abstract][Full Text] [Related]
9. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. Chambers CR; Ritchie S; Pereira BA; Timpson P Mol Oncol; 2021 Dec; 15(12):3242-3255. PubMed ID: 34137158 [TBL] [Abstract][Full Text] [Related]
10. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets. Rossi M; Abdelmohsen K Cells; 2021 Jul; 10(7):. PubMed ID: 34359910 [TBL] [Abstract][Full Text] [Related]
12. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy. Chibaya L; Snyder J; Ruscetti M Semin Cancer Biol; 2022 Nov; 86(Pt 3):827-845. PubMed ID: 35143990 [TBL] [Abstract][Full Text] [Related]
13. Dynamic and scalable assessment of the senescence-associated secretory phenotype (SASP). Malaquin N; Rodier F Methods Cell Biol; 2024; 181():181-195. PubMed ID: 38302239 [TBL] [Abstract][Full Text] [Related]
14. Senescence and senolysis in cancer: The latest findings. Imawari Y; Nakanishi M Cancer Sci; 2024 Jul; 115(7):2107-2116. PubMed ID: 38641866 [TBL] [Abstract][Full Text] [Related]
15. Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy. Jiang B; Zhang W; Zhang X; Sun Y Semin Cancer Biol; 2024 Jun; 101():58-73. PubMed ID: 38810814 [TBL] [Abstract][Full Text] [Related]
16. Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. Zhao B; Wu B; Feng N; Zhang X; Zhang X; Wei Y; Zhang W J Hematol Oncol; 2023 Mar; 16(1):28. PubMed ID: 36945046 [TBL] [Abstract][Full Text] [Related]
17. Cellular senescence in the lung across the age spectrum. Parikh P; Wicher S; Khandalavala K; Pabelick CM; Britt RD; Prakash YS Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L826-L842. PubMed ID: 30785345 [TBL] [Abstract][Full Text] [Related]
19. Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis. Gonzalez-Meljem JM; Martinez-Barbera JP Cell Mol Life Sci; 2021 May; 78(10):4521-4544. PubMed ID: 34019103 [TBL] [Abstract][Full Text] [Related]